

A1  
11. (Amended) The polypeptide of claim 1, comprising at least one of said first or second domains [of any one of claims 2 to 9], wherein said first domain comprises at least one CDR of the V<sub>H</sub> and V<sub>L</sub> region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 82 to 414 (V<sub>L</sub>) and nucleotides 460 to 831 (V<sub>H</sub>) [and/or] and, wherein said second domain comprises at least one CDR of the V<sub>H</sub> and V<sub>L</sub> region comprising the amino acid sequence encoded by the DNA sequence depicted in Figure 8 from nucleotides 847 to 1203 (V<sub>H</sub>) and nucleotides 1258 to 1575 (V<sub>L</sub>).

Claim 12, line 1, delete "any one of claims 1 to 11" and insert --claim 1--.

Claim 13, line 1, delete "any one of claims 1 to 12" and insert --claim 1--.

Claim 14, line 1, delete "any one of claims 1 to 13" and insert --claim 1--.

Claim 16, line 1, delete "or 15".

A2  
17. (Amended) A polynucleotide which upon expression encodes a single-chain multi-functional polypeptide [of any one of claims 1 to 16] comprising

- (a) a first domain comprising a binding-site of an immunoglobulin chain or an antibody specifically recognizing the CD 19 antigen; and
- (b) a second domain comprising a binding site of an immunoglobulin chain or an antibody specifically recognizing the human CD3 antigen.

A3  
19. (Amended) A cell transfected with the polynucleotide of claim 17 or a vector [of claim 18] comprising said polynucleotide.

20. (Amended) A method for the preparation of [the] a single-chain multi-functional polypeptide [of any one of claims 1 to 16 which process] comprising:

- (a) a first domain comprising a binding-site of an immunoglobulin chain or an antibody specifically recognizing the CD 19 antigen; and
- (b) a second domain comprising a binding site of an immunoglobulin chain or an antibody specifically recognizing the human CD3 antigen.

wherein said method comprises cultivating a cell of claim 19, and isolating said polypeptide from the cell [culture].

21. (Amended) A composition comprising [the]

(1) a single-chain multi-functional polypeptide [of any one of claims 1 to 16,]

comprising:

- AB  
Cont'd
- (a) a first domain comprising a binding-site of an immunoglobulin chain or an antibody specifically recognizing the CD 19 antigen; and
  - (b) a second domain comprising a binding site of an immunoglobulin chain or an antibody specifically recognizing the human CD3 antigen;
  - (2) the polynucleotide of claim 17; or
  - (3) the vector [of claim 18] comprising said polynucleotide.

Claim 22, line 2, delete “,”.

Claim 27, line 3, delete “, preferably B-cells”, and line 4, delete “any one of claims 1 to 16” and insert --claim 1,--.

Claim 29, line 1, delete “or 29”.

30. (Amended) A method for the treatment of B-cell malignancies, B-cell mediated autoimmune diseases or the depletion of B-cells comprising administering to a human afflicted with said malignancies, diseases or depletion, an effective amount of: [introducing the polypeptide of any one of claims 1 to 16],

(1) a single-chain multi-functional polypeptide [of any one of claims 1 to 16,]

comprising:

- A4
- (a) a first domain comprising a binding-site of an immunoglobulin chain or an antibody specifically recognizing the CD 19 antigen; and
  - (b) a second domain comprising a binding site of an immunoglobulin chain or an antibody specifically recognizing the human CD3 antigen;
  - (2) the polynucleotide of claim 17; or
  - (3) the vector [of claim 18] comprising said polynucleotide [into a human affected by said malignancies or disease].

31. (Amended) A method for delaying a pathological condition which is caused by B-cell disorders, comprising administering to a human afflicted with said pathological condition, an effective amount of: [introducing the polypeptide of any one of claims 1 to 16],